Kiniksa Pharmaceuticals Competitors and Similar CompaniesClear all

Kiniksa Pharmaceuticals's competitors and similar companies include Genentech, Mankind Pharma and Cipla.

	Kiniksa Pharmaceuticals Kiniksa Pharmaceuticals focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 2015	Founding Date 1976	Founding Date 1995	Founding Date 1935
Type	Type Public	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Lexington, US HQ Hamilton, BM London, GB San Diego, US	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations New Delhi, IN HQ	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 220437% increase	Employees 18,077	Employees 16,2532% increase	Employees 27,764
Financial
Revenue (est.)	Revenue (est.) $677.6m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods $77.7m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)
Gross profit	Gross profit $599.9m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit ₹195b (FY, 2026)
Net income	Net income $59m (FY, 2025)	Net income N/A	Net income N/A	Net income ₹38.7b (FY, 2026)